Eli lilly and company (LLY)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash Flows from Operating Activities
Net Income (Loss) Attributable to Parent

8,318

3,232

-204

2,737

2,408

2,390

4,684

4,088

4,347

5,069

4,328

-2,071

2,953

Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal

309

0

0

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

1,232

1,609

1,567

1,496

1,427

1,379

1,445

1,462

1,373

1,328

1,297

1,122

-1,047

Change in deferred income taxes

-62

-326

787

-439

748

-36

-265

-126

268

-559

-189

442

60

Stock-based compensation expense

312

279

281

255

217

156

144

141

147

231

368

255

-282

Acquired in-process research and development (Note 3)

239

1,980

1,110

30

535

200

57

-

-

-

-

-

-

Net realized investment gains

-

-

-

-

-

-

-

66

-

-

-

-

-

Impairment charges, indefinite lived intangibles

-

-

-

-

-

-

-

205

151

0

0

-

-

Acquired in-process research and development, net of tax

-

-

-

-

-

-

-

0

252

32

58

4,792

-692

Income related to termination of the exenatide collaboration with Amylin

-

-

-

-

-

-

495

787

0

0

-

-

-

Net proceeds from (payments for) terminations of interest rate swaps

-

-

-

-

-

-340

0

0

-

-

-

-

-

Other changes in operating assets and liabilities, net of acquisitions and divestitures

-

-

-

-

-

-

-

-

-

-

-

-

-53

Net marketing investigation charges accrued paid

-

-

-

-

-

-

-

-

-

-

-1,313

1,423

0

Other non-cash operating activities, net

348

472

441

376

263

280

25

187

-17

-178

362

406

-172

Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Operating income (loss) before working capital changes

-

-

-

-

-

-

-

-

-

-

-

-

5,208

Receivables—(increase) decrease

127

996

357

709

304

-117

152

-361

188

319

492

799

-842

Inventories—(increase) decrease

258

-7

253

328

736

307

286

307

-203

-157

179

84

154

Other assets—(increase) decrease

602

980

590

265

288

-673

-116

-231

-642

-340

84

1,648

-355

Income taxes payable—increase (decrease)

-221

-125

3,489

-304

-17

-

-

-

-

-

-

-

-

Accounts payable and other liabilities—increase (decrease)

-477

-284

916

1,123

207

-809

-70

-336

591

-363

-200

-1,608

-990

Net Cash Provided by Operating Activities

4,836

5,524

5,615

4,851

2,964

4,458

5,735

5,304

7,234

6,856

4,335

7,295

5,154

Cash Flows from Investing Activities
Net purchases of property and equipment

1,033

1,210

1,076

1,037

1,066

1,162

1,012

905

672

694

765

947

1,082

Proceeds from disposals of property and equipment

-

-

-

73

92

15

179

22

25

24

17

25

32

Cash released for pending acquisition (Note 3)

-

-

-

-

-5,405

5,405

0

0

-

-

-

-

-

Proceeds from sales and maturities of short-term investments

136

2,552

4,852

1,642

2,161

4,054

3,320

2,547

1,807

-

-

-

-

Purchases of short-term investments

42

112

3,389

1,327

842

1,637

1,531

2,172

2,058

686

-399

-957

376

Proceeds from sales of noncurrent investments

609

3,509

2,586

2,086

3,068

11,009

11,235

4,355

2,138

584

1,107

1,597

800

Purchases of noncurrent investments

247

837

4,611

4,346

3,226

9,802

14,041

7,618

4,459

1,067

432

2,412

750

Proceeds from sale of product rights

-

-

-

-

410

0

0

-

-

-

-

-

-

Purchase of product rights

-

-

-

-

-

308

24

138

632

442

0

0

-

Purchases of in-process research and development

-

-

-

55

560

95

57

0

-

-

-90

-122

-111

Cash paid for acquisitions, net of cash acquired (Note 3)

6,917

0

882

45

5,283

551

43

199

307

609

0

6,083

2,673

Purchases of in-process research and development

319

1,807

1,086

-

-

-

-

-

388

50

-

-

-

Net change in loan to collaboration partner

-

-

-

-

-

-

-

-

-165

0

0

-

-

Proceeds from prepayment of revenue-sharing obligation

-

-

-

-

-

-

-

1,212

0

0

-

-

-

Other investing activities, net

248

187

175

130

133

24

97

-64

112

219

94

284

166

Net Cash Used for Investing Activities

-8,082

1,906

-3,783

-3,139

26

-3,909

-2,072

-2,832

-4,824

-3,159

142

-7,268

-4,328

Cash Flows from Financing Activities
Dividends paid

2,409

2,311

2,192

2,158

2,127

2,101

2,120

2,187

2,180

2,165

2,152

2,056

1,853

Net change in short-term borrowings

995

-2,197

1,397

1,293

-2,680

2,680

0

0

-134

125

-5,824

5,060

-468

Proceeds from issuance of long-term debt

6,556

2,477

2,232

1,206

4,454

992

0

0

-

-

2,400

0

2,512

Repayments of long-term debt

2,866

1,009

630

0

1,955

1,034

10

1,511

61

1

0

649

1,059

Purchases of common stock

4,400

4,150

299

600

749

800

1,698

721

0

0

-

-

-

Net proceeds from Elanco initial public offering (Note 19)

0

1,659

0

0

-

-

-

-

-

-

-

-

-

Other financing activities, net

-200

-372

-364

-300

-52

96

0

0

6

19

42

-8

24

Net Cash Provided by Financing Activities

-2,324

-5,904

142

-559

-3,111

-166

-3,829

-4,419

-2,369

-2,021

-5,533

2,346

-844

Effect of exchange rate changes on cash and cash equivalents

-89

-63

-20

-236

-85

-341

-21

43

-110

-144

21

-96

129

Net decrease in cash and cash equivalents

-5,660

1,462

1,954

915

-205

41

-188

-1,903

-70

1,530

-1,033

2,276

111